Controversial Aduhelm To Administered At More Than 300 Hospitals: Nikkei's
Alzamend Recruits Altasciences To Conduct Early-Stage Trial Of Its Alzheimer's Candidate
Analysts Predict Volatility In Biogen Shares Until March 2021
Neurotrope Alzheimer's Candidate Could Generate Revenue Beginning In 2024, Analyst Says